S. Barrett

发表

IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients

H. Sasano, L. Hayward, R. Stein, 2017, Breast Cancer Research and Treatment.

Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

N. Rahman, M. Dowsett, P. Ellis, 2015 .

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.

P. Fasching, F. Couch, K. Gelmon, 2021, European journal of cancer.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Anti-sleeping sickness drugs and cancer chemotherapy.

M. Barrett, S. Barrett, 2000, Parasitology today.

Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.

Andreas Schätzlein, Chris Twelves, Carol McCormick, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

Paul Ellis, Nazneen Rahman, Alexander Gutin, 2018, Nature Medicine.

Abstract S6-01:BRCA1methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012)

A. Ashworth, C. Perou, N. Rahman, 2017 .

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial.

R. Glasspool, P. Vasey, S. Kaye, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Oncoplastic breast conservation does not lead to a delay in the commencement of adjuvant chemotherapy in breast cancer patients.

L. Romics, S. Barrett, S. Stallard, 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[Intraoperative, postoperative and long-term oncosurgical safety of therapeutic mammaplasty].

L. Romics, S. Barrett, S. Stallard, 2013, Orvosi hetilap.

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

S. Aamdal, D. Pietersma, D. Tan, 2012, British Journal of Cancer.

Pharmacodynamic effects in patients treated with 6 hour infusion of the demethylating agent 5-aza-2 ' deoxycytidine (decitabine)

Robert Brown, I. Judson, S. Kaye, 2005 .

Gut microbial short chain fatty acids are associated with pathological complete response (pCR) after neoadjuvant chemotherapy for breast cancer

I. Macpherson, J. Fraser, K. Gerasimidis, 2020 .

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial

A. Ashworth, C. Perou, N. Rahman, 2018, Nature Medicine.